Indivior stock heads into the open after a 0.7% Nasdaq drop
Published on 09/17/2026 at 07:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Indivior stock closed at USD 34.22 on the Nasdaq on September 15, 2026, losing 0.73% from the prior session. The shares traded between an intraday low of USD 33.60 and a high of USD 34.58, leaving the close between those levels. Indivior stock underperformed the broader market, with the Nasdaq Composite edging higher the same day.
September 15, 2026 in numbers
Indivior Pharmaceuticals, Inc. (ISIN GB00BYZ0C031, Nasdaq: INDV) saw its Nasdaq-listed shares pressured on September 15, 2026 after the company terminated a long-running supply agreement with Reckitt Benckiser effective January 2027, according to a report from Ad-hoc-news. On that day the stock closed at USD 34.22, down 0.73%, with trading volume roughly in line with its recent average. The move left Indivior shares about 43.2% below an average analyst price target of USD 49.00 as of September 15, 2026, as highlighted by MarketScreener data cited in the same Ad-hoc-news article. The closing level kept the shares comfortably within their documented 52-week trading range.
Today’s focus for Indivior
Today, investors are set to monitor any follow-up commentary from Indivior or analysts on the implications of the terminated Reckitt Benckiser supply agreement, which has been flagged as a key factor for future sales and margin visibility by recent coverage on Investing.com. Broader market sentiment on healthcare and pharmaceuticals, along with any sector updates related to opioid-treatment and central nervous system therapies, may also shape trading in Indivior stock heading into today’s US session.
